Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026 - News and Statistics

FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too

Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic

FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract Pharma

Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times

Endpoints NewsParabilis Medicines charts $413M IPO to back peptide pipeline

FierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC

PharmaVoiceHouse bill aims to crack down on China biotech deals

PharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problems

FierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’